Detailed price information for Rigel Pharmaceuticals (RIGL-Q) from The Globe and Mail including charting and trades.

Rigel Pharmaceuticals RIGL is scheduled to report third-quarter 2025 results on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $61.6 ...

Rigel Pharmaceuticals (NASDAQ:RIGL) is gearing up to announce its quarterly earnings on Tuesday, 2025-11-04. Here's a quick overview of what investors should know before the release. Analysts are ...

Rigel will participate in one-on-one meetings and present a company overview on Wednesday, September 3, at 8:35 a.m. ET. 2025 Wells Fargo Healthcare Conference in Boston, MA Rigel will participate in ...

Rigel Pharmaceuticals RIGL will release its quarterly earnings report on Tuesday, 2025-08-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Rigel Pharmaceuticals ...

Rigel’s IRAK1/4 inhibitor, R289, has shown promising results in a Phase 1b trial for relapsed/refractory lower-risk myelodysplastic syndrome (LR-MDS). The initial data presented at ASH 2024 ...

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. Total costs and expenses were $40 ...

Rigel Pharmaceuticals has benefitted from Tavalisse's sustained outperformance, driving increasing net income and attractive ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has more than four decades of experience in commercial and ...